Thrombosis with Thrombocytopenia Syndrome, or TTS, is a rare but serious condition that combines abnormal blood clotting (thrombosis) with a reduced number of platelets (thrombocytopenia). It came to wide attention during mass immunization against COVID-19, particularly with adenovirus-vectored vaccines.
Recognizing TTS and classifying cases consistently is important for both clinical care and vaccine safety monitoring. To support this, the Brighton Collaboration developed standardized case definitions for TTS and VITT.
Watch the video: https://youtu.be/gYDcKSevhAs
What Are TTS and VITT?
Thrombosis is the formation of a blood clot, which can occur in veins or arteries anywhere in the body. Symptoms depend on where the clot forms, ranging from a sudden, severe headache or neurological deficits (brain), to shortness of breath and chest pain (heart or lungs), abdominal pain (abdominal organs), or painful limb swelling (arms or legs).
Thrombocytopenia may cause no symptoms and is often detected only through a platelet count. When there is a large drop in platelet count, there may be signs of spontaneous bleeding, such as small red spots on the skin (petechiae), bruising, or bleeding from the nose or gums.
VITT is a specific immune-mediated form of TTS, which follows vaccine. In VITT antibodies to Platelet Factor 4 (PF4) activate platelets and trigger widespread clotting, often in more than one location in the body.
When Should TTS or VITT Be Suspected?
TTS or VITT should be suspected when:
- Thrombosis or thrombocytopenia begins 4 to 42 days after vaccination
- A severe, persistent headache begins 5 to 30 days after vaccination
If there is clinical evidence of thrombosis without bleeding, a platelet count should be obtained to check for thrombocytopenia.
Why Standardized Case Definitions Matter
The Brighton Collaboration case definitions classify cases by level of diagnostic certainty.
For TTS:
Level 2 – Probable case
Clinical evidence of thrombosis, thrombocytopenia, onset 4 to 42 days after vaccination, and no more plausible alternative explanation.
Level 1 – Definite case
The same criteria, with thrombosis confirmed by imaging, surgery, or pathology, or a severe persistent headache with a markedly elevated D-dimer.
For VITT, the case definition adds a fifth criterion, the presence of anti-PF4 antibodies, alongside thrombosis, thrombocytopenia, timing after vaccination, and a markedly elevated D-dimer. Cases are classified as possible (Level 3), probable (Level 2), or definite (Level 1) depending on how many criteria are met.
Supporting Global Vaccine Safety Monitoring
Because TTS and VITT have been reported following immunization, consistent case identification is essential for monitoring potential adverse events following vaccination.
Standardized case definitions allow researchers, clinicians, and regulators to classify cases consistently across countries and studies, strengthening global vaccine safety surveillance and improving confidence in vaccine safety systems.
Educational resources like this video help clinicians and public health professionals better understand TTS and VITT and apply standardized definitions in research and surveillance.
